Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;2(1):100131.
doi: 10.1016/j.soi.2025.100131. Epub 2025 Feb 13.

Real world experience with omission of therapeutic lymph node dissection in clinical stage III malignant melanoma treated with checkpoint or kinase inhibition systemic therapy

Michael J Kirsch  1 , Elliott J Yee  1 , Patrick Hosokawa  2 , William Robinson  3 , Theresa Medina  3 , Luke Mantle  3 , John Blair Hamner  4 , Martin D McCarter  5 , Camille L Stewart  6
Affiliations

Real world experience with omission of therapeutic lymph node dissection in clinical stage III malignant melanoma treated with checkpoint or kinase inhibition systemic therapy

Michael J Kirsch et al. Surg Oncol Insight. 2025 Mar.

Abstract

Background: Management of clinical stage III melanoma, which historically was treated with surgical therapeutic lymph node dissection (TLND), has changed significantly due to the introduction of effective systemic therapies including immune checkpoint and BRAF/MEK inhibitors. We asked how surgical interventions changed progression free survival and overall survival in this population.

Methods: The Flatiron Health electronic health records database for Advanced Melanoma was queried for patients with clinical stage III melanoma treated between 2018 and 2022 with systemic therapy. Patients were stratified by receipt of TLND.

Results: There were 533 patients with clinical stage III melanoma treated with systemic therapy identified; 235 (44.1 %) underwent TLND prior to systemic therapy, 17 (3.2 %) underwent TLND after receipt of systemic therapy, and 281 (52.7 %) received systemic therapy alone and did not have surgery. There were 38.1 % (n = 203) who experienced disease progression at 2 years. Patients in the no surgery group had the best 2-year progression free survival (67.3 %) compared to the upfront surgery (58.3 %) and surgery after systemic therapy groups (23.5 %, p = 0.001), and there was no difference in 2-year overall survival (82.2 % vs 80.0 % vs 82.3 %, p = 0.81). These findings persisted on multivariable analysis.

Conclusions: In this modern era dataset, more than half of patients with clinical stage III melanoma were treated with systemic therapy alone, despite guideline recommendations for TLND. They had superior progression free survival and similar overall survival compared to those also treated with potentially morbid surgery. Randomized data are needed to evaluate appropriate omission of surgery in this patient population.

Keywords: Immune checkpoint inhibitors; Immunotherapy; Lymphadenectomy; Stage III melanoma; Therapeutic lymph node dissection.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Stewart is a consultant for Merit Medical. Dr. Medina reports Institutional Principal Investigator (institutional funding) for the following: Bristol Myers Squibb, Genentech, Inc., Iovance pharmaceuticals, Merck & Co., Inc., Agenus, Other-Anaveon, Other-Bioatla, Inc, Other-Infla-Rx, Other-Moderna, Other-Replimune, Other-TriSalus, Other-Ultimovacs, Pfizer Inc., Regeneron Pharmactcls, SeaGen, and Immatics. All other authors had nothing to report.

Figures

Fig. 1.
Fig. 1.
Progression free survival of clinical stage III melanoma by treatment strategy. Patients treated with systemic therapy alone and no surgery (green) had superior progression free survival compared to patients who underwent upfront therapeutic lymph node dissection followed by systemic therapy (red), and therapeutic lymph node dissection after treatment with systemic therapy (blue) (p = 0.001).
Fig. 2.
Fig. 2.
Overall survival of clinical stage III melanoma by treatment strategy. Overall survival did not differ if patients were treated with systemic therapy alone and no surgery (green), upfront therapeutic lymph node dissection followed by systemic therapy (red), or therapeutic lymph node dissection after treatment with systemic therapy (blue) (p = 0.81).
See this image and copyright information in PMC

References

    1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. 2017 CA Cancer J Clin 2017;67(6):472–492. 10.3322/caac.21409 - DOI - PMC - PubMed
    1. Diller ML, Martin BM, Delman KA. Lymph node dissection for stage iii melanoma. 2015/04// Surg Oncol Clin N Am 2015;24(2):261–277. 10.1016/j.soc.2014.12.005 - DOI - PubMed
    1. Rebecca VW, Sondak VK, Smalley KSM. A brief history of melanoma: from mummies to mutations. 2012/04// Melanoma Res 2012;22(2):114–122. 10.1097/CMR.0b013e328351fa4d - DOI - PMC - PubMed
    1. Urist MM, Maddox WA, Kennedyy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. 1983/06/01/Cancer. 1983;51(11):2152–2156. 10.1002/1097-0142(19830601)51:11<2152::AID-CNCR2820511134>3.0.CO;2-7 - DOI - PubMed
    1. Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma – a systematic review of the literature. 2017/09// Eur J Surg Oncol 2017;43(9):1760–1767. 10.1016/j.ejso.2017.07.003 - DOI - PubMed